Cost-effectiveness analysis of anlotinib plus penpulimab versus sorafenib in the treatment of unresectable hepatocellular carcinoma.

ABSTRACT: The APOLLO trial demonstrated that anlotinib plus penpulimab significantly prolonged progression-free survival (PFS) and overall survival compared to sorafenib in patients with unresectable hepatocellular carcinoma (HCC). However, its cost-effectiveness remains uncertain. This study aimed to evaluate the cost-effectiveness of this regimen from the perspective of the Chinese healthcare system. We constructed a partitioned survival model comprising three health states to evaluate the cost-effectiveness of anlotinib plus penpulimab versus sorafenib for unresectable HCC. Over a 10-y time horizon, we compared the total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) between two groups. The robustness of the results was validated through one-way sens

SUBMITTER: Luo J 

PROVIDER: S-EPMC12674322 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature